Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases

MT Newswires Live06-03

Cabaletta Bio's (CABA) experimental therapy, rese-cel, showed potential as a treatment for autoimmune diseases, including myositis, lupus and systemic sclerosis, based on new clinical data, the drugmaker said Wednesday.

A phase 1/2 myositis study showed that most patients with dermatomyositis and antisynthetase syndrome who stopped immunosuppressants have improved at 16 weeks, with some responses lasting up to 1.5 years, the company said.

In systemic sclerosis, patients showed improvements in lung and skin symptoms, and most reached meaningful response scores at 36 weeks while off immunosuppressants, the company said.

In lupus, patients who received pre-conditioning mostly stayed in remission at 12 months while off immunosuppressants and on low or no steroids, the company added.

Cabaletta said it plans to start a registrational systemic sclerosis study in late 2026 and expand development in lupus and pediatric programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640904573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640904573","market":"sh","top_or_hot":-1,"title":"Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a>'s (CABA) experimental therapy, rese-cel, showed potential as a treatment for autoimmune diseases, including myositis, lupus and systemic sclerosis, based on new clinical data, the drugmaker said Wednesday.</p><p>A phase 1/2 myositis study showed that most patients with dermatomyositis and antisynthetase syndrome who stopped immunosuppressants have improved at 16 weeks, with some responses lasting up to 1.5 years, the company said.</p><p>In systemic sclerosis, patients showed improvements in lung and skin symptoms, and most reached meaningful response scores at 36 weeks while off immunosuppressants, the company said.</p><p>In lupus, patients who received pre-conditioning mostly stayed in remission at 12 months while off immunosuppressants and on low or no steroids, the company added.</p><p>Cabaletta said it plans to start a registrational systemic sclerosis study in late 2026 and expand development in lupus and pediatric programs.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a>'s (CABA) experimental therapy, rese-cel, showed potential as a treatment for autoimmune diseases, including myositis, lupus and systemic sclerosis, based on new clinical data, the drugmaker said Wednesday.</p><p>A phase 1/2 myositis study showed that most patients with dermatomyositis and antisynthetase syndrome who stopped immunosuppressants have improved at 16 weeks, with some responses lasting up to 1.5 years, the company said.</p><p>In systemic sclerosis, patients showed improvements in lung and skin symptoms, and most reached meaningful response scores at 36 weeks while off immunosuppressants, the company said.</p><p>In lupus, patients who received pre-conditioning mostly stayed in remission at 12 months while off immunosuppressants and on low or no steroids, the company added.</p><p>Cabaletta said it plans to start a registrational systemic sclerosis study in late 2026 and expand development in lupus and pediatric programs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640904573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640904573","pubTimestamp":1780489909,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cabaletta Bio's  experimental therapy, rese-cel, showed potential as a treatment for autoimmune diseases, including myositis, lupus and systemic sclerosis, based on new clinical data, the drugmaker said Wednesday.A phase 1/2 myositis study showed that most patients with dermatomyositis and antisynthetase syndrome who stopped immunosuppressants have improved at 16 weeks, with some responses lasting up to 1.5 years, the company said.In systemic sclerosis, patients showed improvements in lung and skin symptoms, and most reached meaningful response scores at 36 weeks while off immunosuppressants, the company said.In lupus, patients who received pre-conditioning mostly stayed in remission at 12 months while off immunosuppressants and on low or no steroids, the company added.Cabaletta said it plans to start a registrational systemic sclerosis study in late 2026 and expand development in lupus and pediatric programs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CABA":"Cabaletta Bio"},"translate_title":"Cabaletta Bio的Rese-cel显示出治疗自身免疫性疾病的潜力","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CABA":1.5},"content_text":"Cabaletta Bio's (CABA) experimental therapy, rese-cel, showed potential as a treatment for autoimmune diseases, including myositis, lupus and systemic sclerosis, based on new clinical data, the drugmaker said Wednesday.A phase 1/2 myositis study showed that most patients with dermatomyositis and antisynthetase syndrome who stopped immunosuppressants have improved at 16 weeks, with some responses lasting up to 1.5 years, the company said.In systemic sclerosis, patients showed improvements in lung and skin symptoms, and most reached meaningful response scores at 36 weeks while off immunosuppressants, the company said.In lupus, patients who received pre-conditioning mostly stayed in remission at 12 months while off immunosuppressants and on low or no steroids, the company added.Cabaletta said it plans to start a registrational systemic sclerosis study in late 2026 and expand development in lupus and pediatric programs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640904573","isCrawlerRequest":true}